ALN-AGT01 RVR: ALN-AGT01 RVR will be administered subcutaneously (SC)
Placebo: Placebo will be administered SC
Zilebesiran: Zilebesiran will be administered SC
Study summary
The purpose of this study is to evaluate the efficacy, pharmacodynamics (PD), and safety of ALN-AGT01 RVR in participants with mild to moderate hypertension pretreated with zilebesiran.
Eligibility
Sex
ALL
Min age
18 Years
Max age
75 Years
Healthy volunteers
No
Part A: Inclusion Criteria
* Is an adult participant with a mean seated office systolic blood pressure (SBP) of at least 130 mmHg and no more than than 170 mmHg
* Either not taking antihypertensive medication or on stable therapy with up to 2 antihypertensive medications
Part B: Inclusion Criteria
* Is an adult participant with a mean seated office SBP of at least 140 mmHg and no more than 170 mmHg
* Has discontinued all prior antihypertensive medication other than a calcium channel blocker (CCB) and/or thiazide/thiazide-like diuretic (if taking) for at least 3 weeks
Both Parts: Exclusion Criteria
* Has known secondary hypertension or serum potassium more than 5 mmol/L
* Has an estimated glomerular filtration rate (eGFR) less than 30 mL/min/1.73m\^2
Note: other protocol defined inclusion / exclusion criteria apply
Primary outcome measure(s)
Part A: Percentage recovery from baseline in serum AGT — Up to Day 4
Part B: Percentage recovery from baseline in mean seated office SBP — At Day 4 and Day 7
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time on our Cookie Policy page. See also our Privacy Policy.